The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
RB1: a prototype tumor suppressor and an enigma
Open accessAbstract
The retinoblastoma susceptibility gene (RB1) was the first tumor suppressor gene to be molecularly defined.RB1 mutations occur in almost all familial and sporadic forms of retinoblastoma, and this gene is mutated at variable frequencies in a variety of other human cancers. Because of its early discovery, the recessive nature of RB1 mutations, and its frequency of inactivation,RB1 is often described as a prototype for the class of tumor suppressor genes. Its gene product (pRB) regulates transcription and is a negative regulator of cell proliferation. Although these general features are well established, a precise description of pRB's mechanism of action has remained elusive. Indeed, in many regards, pRB remains an enigma. This review summarizes some recent developments in pRB research and focuses on progress toward answers for the three fundamental questions that sit at the heart of the pRB literature: What does pRB do? How does the inactivation of RB change the cell? How can our knowledge of RB function be exploited to provide better treatment for cancer patients?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Leduc, C., Claverie, P., Eymin, B., Col, E., Khochbin, S., Brambilla, E. M., & Gazzéri, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209446 · Cited by 74
RetractedRETRACTED: The inner centromere–shugoshin network prevents chromosomal instability
Tanno, Y., Susumu, H., Kawamura, M., Sugimura, H., Honda, T., & Watanabe, Y. (2015) · Science · doi:10.1126/science.aaa2655 · Cited by 49
RetractedSherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 2×
“The inactivation of pRB compromises the ability of cells to exit the cell cycle, and this places them in a state that is highly susceptible to oncogenic proliferation (for a review, see Hinds and Weinberg 1994; Weinberg 1995; Sherr 1996; Nevins 2001).”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product
Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017 · cited 1×
“These tumors develop from progenitor cells that are dependent on Mdm2 (Xu et al. 2009), and, as they also often express high levels of Mdm4 (Laurie et al. 2006), they may be targetable by agents such as Nutlin that activate p53 signaling (Elison et al. 2006; Laurie et al. 2006, 2007).”
BackgroundA human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 2×
“The development of effective inhibitors for Cdk4/6 kinases has been one of the most impactful applications of pRB research (Fry et al. 2004; for review, see Sherr et al. 2016).”
BackgroundMethodSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Recent work has suggested that Notch signaling may be important in mouse models of small-cell lung cancer, one of the most common types of RB1 mutant cancers (George et al. 2015).”
BackgroundComprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900 · cited 1×
“…accelerated approval to a combination of the Cdk4/6 inhibitor palbociclib and letrozole for the treatment of hormone receptor-positive advanced breast cancer (Finn et al. 2015), and the efficacy of palbociclib in this setting has been confirmed in subsequent large-scale trials (Turner et al. 2015).”
BackgroundPalbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Cited by
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Cell cycle regulation: p53-p21-RB signaling
Engeland, K. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00988-z · Cited by 1,274
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 800
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
Engeland, K. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.172 · Cited by 656
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
“Our understanding of TSGs mostly comes from the preliminary study of retinoblastoma genes, the first discovery of a TSG, and mutation causes retinoblastoma in children.(6,7) This is a genetic disease caused by the retinoblastoma susceptibility gene (Rb1) gene inactivation mutation.”
BackgroundMulti-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.004 · Cited by 408
Uxa, S., Castillo-Binder, P., Kohler, R., Stangner, K., Müller, G. A., & Engeland, K. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00823-x · Cited by 306
Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes.
Fischer, M., & Müller, G. A. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1360836 · Cited by 255
Biphasic cell cycle defect causes impaired neurogenesis in down syndrome
Sharma, V., Nehra, S., Do, L. H., Ghosh, A., Deshpande, A. J., & Singhal, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1007519 · Cited by 14
“RB1, a tumor suppressor gene, acts by preventing progression from G1 to the S phase (Dyson, 2016).”
Background
Metadata
- Authors
- Dyson, N. J.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-07-01
- Volume
- 30
- Issue
- 13
- Pages
- 1492-1502
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2471978271
- Cited by
- 435
- References
- 151
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.